A global study shows that 77% of patients observed a reduction in tumors with zongertinib, an innovative treatment for HER2 lung cancer.

A study conducted in 85 locations around the world evaluated the effectiveness of zongertinib as an initial treatment for patients with advanced lung cancer and the HER2 genetic mutation. The results were promising: 77% of patients observed a reduction in tumors, and 8% experienced complete disappearance of them.

Professor Sanjay Popat, the coordinator of the study, emphasized the importance of these results, mentioning that previously there were no targeted therapies for these patients, who were subjected to intense chemotherapy treatments.

Zongertinib offers a new opportunity to improve outcomes and the quality of life for patients. One example is Susan Gasson, a 74-year-old patient who experienced a reduction in cancer and minimal side effects after two years of treatment. The next step will be a phase III study to compare zongertinib with other treatments, such as chemotherapy.